Evidence map›Paper›PMID 22610117›Full record

ArticleNature genetics2012

Extremely low-coverage sequencing and imputation increases power for genome-wide association studies.

Bogdan Pasaniuc, Nadin Rohland, Paul J McLaren, Kiran Garimella, Noah Zaitlen, Heng Li, Namrata Gupta, Benjamin M Neale, Mark J Daly, Pamela Sklar and 14 more

Abstract read
In one paragraph

Article in Nature genetics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 169 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
169citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

169 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

109 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Bogdan PasaniucDepartment of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA. bpasaniu@hsph.harvard.edu
Nadin Rohland
Paul J McLaren
Kiran Garimella
Noah Zaitlen
Heng Li
Namrata Gupta
Benjamin M Neale
Mark J Daly
Pamela Sklar
Patrick F Sullivan
Sarah Bergen
Jennifer L Moran
Christina M Hultman
Paul Lichtenstein
Patrik Magnusson
Shaun M Purcell
David W Haas
Liming Liang
Shamil Sunyaev
Nick Patterson
Paul I W de Bakker
David Reich
Alkes L Price

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
AIDS Clinical Trials Group NetworkU01AI068636 · NIAID · SOCIAL AND SCIENTIFIC SYSTEMS, INC. · PI KURITZKES, DANIEL R. · 2006 to 2010
$147.1M
The impact of HIV viral diversity and cellular immunity on HIV pathogenesisP30AI060354 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI ROBERT A. PARKER · 2004 to 2026
$94.4M
Statistical and Data Management Center for the AIDS Clinical Trials GroupU01AI068634 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI HUGHES, MICHAEL DAVID · 2006 to 2010
$71.9M
University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit 2024 SupplementUM1AI069423 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, MINA CHRISTINE HOSSEINIPOUR · 2012 to 2026
$71.8M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
UCSD Department of Medicine HIV/AIDS Clinical Trials UnitUM1AI069432 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI TIMOTHY J. WILKIN · 2012 to 2026
$50.4M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
Weill Cornell Medicine - Rutgers New Jersey Medical School Clinical Trials UnitUM1AI069419 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI ROY M. GULICK · 2012 to 2026
$44.6M
Case Clinical Trials Unit: Administrative Supplement NOSI AI-20-031.UM1AI069501 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI George Yendewa · 2012 to 2026
$40.4M
Risk Factors for Onset and Persistence of TMDU01DE017018 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DIATCHENKO, LUDA, FILLINGIM, ROGER B · 2005 to 2016
$35.9M
NCRR NIH HHS KL2 RR024977NCRR NIH HHS RR024975NCRR NIH HHS TL1 RR024978NCRR NIH HHS UL1 RR024975NHGRI NIH HHS R01 HG006399NIAID NIH HHS AI068636NIAID NIH HHS AI069415NIAID NIH HHS AI069419NIAID NIH HHS AI069423NIAID NIH HHS AI069424NIAID NIH HHS AI069428NIAID NIH HHS AI069432NIAID NIH HHS AI069434NIAID NIH HHS AI069450NIAID NIH HHS AI069452NIAID NIH HHS AI069465NIAID NIH HHS AI069471NIAID NIH HHS AI069472NIAID NIH HHS AI069474NIAID NIH HHS AI069477NIAID NIH HHS AI069484NIAID NIH HHS AI069495NIAID NIH HHS AI069501NIAID NIH HHS AI069502NIAID NIH HHS AI069511NIAID NIH HHS AI069513NIAID NIH HHS AI069532NIAID NIH HHS AI069556NIAID NIH HHS AI077505NIAID NIH HHS AI25859NIAID NIH HHS AI27661NIAID NIH HHS AI28568NIAID NIH HHS AI30914NIAID NIH HHS AI34835NIAID NIH HHS AI34853NIAID NIH HHS AI38844NIAID NIH HHS AI46370NIAID NIH HHS AI68634NIAID NIH HHS AI69467NIAID NIH HHS P-30-AI060354NIAID NIH HHS P30 AI060354NIAID NIH HHS R01 AI028568NIAID NIH HHS R01 AI030914NIAID NIH HHS R01 AI077505NIAID NIH HHS R37 AI028568NIAID NIH HHS U01 AI025859NIAID NIH HHS U01 AI027661NIAID NIH HHS U01 AI032782NIAID NIH HHS U01 AI034835NIAID NIH HHS U01 AI034853NIAID NIH HHS U01 AI038844NIAID NIH HHS U01 AI046370NIAID NIH HHS U01 AI068634NIAID NIH HHS U01 AI068636NIAID NIH HHS U01 AI069415NIAID NIH HHS U01 AI069419NIAID NIH HHS U01 AI069423NIAID NIH HHS U01 AI069424NIAID NIH HHS U01 AI069428NIAID NIH HHS U01 AI069432NIAID NIH HHS U01 AI069434NIAID NIH HHS U01 AI069450NIAID NIH HHS U01 AI069452NIAID NIH HHS U01 AI069465NIAID NIH HHS U01 AI069467NIAID NIH HHS U01 AI069471NIAID NIH HHS U01 AI069472NIAID NIH HHS U01 AI069474NIAID NIH HHS U01 AI069477NIAID NIH HHS U01 AI069484NIAID NIH HHS U01 AI069495NIAID NIH HHS U01 AI069501NIAID NIH HHS U01 AI069502NIAID NIH HHS U01 AI069511NIAID NIH HHS U01 AI069513NIAID NIH HHS U01 AI069532NIAID NIH HHS U01 AI069556NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI069415NIAID NIH HHS UM1 AI069419NIAID NIH HHS UM1 AI069423NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069428NIAID NIH HHS UM1 AI069432NIAID NIH HHS UM1 AI069434NIAID NIH HHS UM1 AI069450NIAID NIH HHS UM1 AI069452NIAID NIH HHS UM1 AI069465NIAID NIH HHS UM1 AI069467NIAID NIH HHS UM1 AI069471NIAID NIH HHS UM1 AI069472NIAID NIH HHS UM1 AI069474NIAID NIH HHS UM1 AI069477NIAID NIH HHS UM1 AI069484NIAID NIH HHS UM1 AI069495NIAID NIH HHS UM1 AI069501NIAID NIH HHS UM1 AI069502NIAID NIH HHS UM1 AI069511NIAID NIH HHS UM1 AI069513NIAID NIH HHS UM1 AI069532NIAID NIH HHS UM1 AI069556NIDCR NIH HHS U01 DE017018NIDDK NIH HHS P30 DK043351NIEHS NIH HHS T32 ES007142NIMH NIH HHS 5RC2MH089905NIMH NIH HHS R01 MH084676NIMH NIH HHS R01 MH089004NIMH NIH HHS R01 MH089025NIMH NIH HHS R01 MH089208NIMH NIH HHS R01MH089208NIMH NIH HHS R01 MH089482NIMH NIH HHS R01 MH095034NIMH NIH HHS RC2 MH089905PHS HHS AL32782
6 · The paper itself

Abstract

Genome-wide association studies (GWAS) have proven to be a powerful method to identify common genetic variants contributing to susceptibility to common diseases. Here, we show that extremely low-coverage sequencing (0.1-0.5×) captures almost as much of the common (>5%) and low-frequency (1-5%) variation across the genome as SNP arrays. As an empirical demonstration, we show that genome-wide SNP genotypes can be inferred at a mean r(2) of 0.71 using off-target data (0.24× average coverage) in a whole-exome study of 909 samples. Using both simulated and real exome-sequencing data sets, we show that association statistics obtained using extremely low-coverage sequencing data attain similar P values at known associated variants as data from genotyping arrays, without an excess of false positives. Within the context of reductions in sample preparation and sequencing costs, funds invested in extremely low-coverage sequencing can yield several times the effective sample size of GWAS based on SNP array data and a commensurate increase in statistical power.

Indexed as

ExomeGenome-Wide Association StudyHumansPolymorphism, Single NucleotideSequence Analysis, DNA

Identifiers

PMID22610117
PMCPMC3400344

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.